Online inquiry

IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4110MR)

This product GTTS-WQ4110MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets oxLDL gene. The antibody can be applied in Atherosclerosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000041.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 348
UniProt ID P02649
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4110MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5645MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ12516MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ554MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ11200MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ8462MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ4348MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ11690MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ15956MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW